Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
248282-01-1CCc1cccc2c1c(O)c(C(=O)N(CC)c1ccccc1)c(=O)n2CDIKSYHCCYVYKRO-UHFFFAOYSA-NPaquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.
248282-01-1Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
VerwendenPaquinimod is a S100A9 inhibitor preventing S100A9 binding to TLR-4. Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Paquinimod treatment of collagenase-induced OA (CIOA) resulted in significantly reduced synovial thickening (57%), osteophyte size at the medial femur (66%) and cruciate ligaments (67%) and cartilage damage at the medial tibia (47%) and femur (75%; n=7, untreated n=6). Paquinimod reduces leukocyte recruitment during sterile inflammation. Paquinimod also reduced priming of proinflammatory effector CD4(+) T cells.
DTXSID90179537CHEMBL67776